Actinium Pharmaceuticals, Inc. (ATNM) compared with its closest peers (PDSB, CRVO, APLM, LITS, MIRA): P/E 3.0 vs industry 17.0. Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| PDS Biotechnology Corporation (PDSB) | $40.23M | — |
| CervoMed Inc. (CRVO) | $39.61M | -2.6 |
| Apollomics, Inc. (APLM) | $37.46M | -0.2 |
| Lite Strategy, Inc. (LITS) | $34.02M | — |
| MIRA Pharmaceuticals, Inc. (MIRA) | $33.62M | -1.1 |
| Actuate Therapeutics Inc (ACTU) | $32.54M | -5.8 |
| IGC Pharma, Inc. (IGC) | $31.49M | -5.6 |
| Lantern Pharma Inc. (LTRN) | $30.17M | -1.9 |
| Daré Bioscience, Inc. (DARE) | $29.74M | -1.6 |
| BeyondSpring Inc. (BYSI) | $29.61M | -80.0 |
| Stock P/E | 3.0 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
| vs Sector | -86.3% |
| vs Industry | -82.4% |
ATNM overview · ATNM earnings · ATNM financials · ATNM KPIs · ATNM investor relations · ATNM ownership · ATNM filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.